Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 11/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.74 |
| ▸ | MAPT | P10636 | 10/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.74 |
| ▸ | POLB | P06746 | 10/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.74 |
| ▸ | APEX1 | P27695 | 8/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.74 |
| ▸ | MEN1 | O00255 | 7/20 | 0.74 |
| ▸ | RECQL | P46063 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.74 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.74 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.65 |
| ▸ | CTDSP1 | Q9GZU7 | 4/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.64 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.63 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.63 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6393879 | 1.00 | TDP1 (0.74) | TDP1KDM4EMAPTALDH1A1POLB | |
| SCHEMBL6391161 | 0.86 | TDP1 (0.83) | TDP1KDM4EMAPTALDH1A1POLB | |
| SCHEMBL6391164 | 0.86 | TDP1 (0.83) | TDP1KDM4EMAPTALDH1A1POLB | |
| SCHEMBL6393742 | 0.84 | TDP1 (0.79) | TDP1KDM4EMAPTALDH1A1POLB | |
| SCHEMBL6393226 | 0.84 | TDP1 (0.79) | TDP1KDM4EMAPTALDH1A1POLB | |
| SCHEMBL46215 | 0.83 | ENPP2 (0.75) | TDP1KDM4EMAPTALDH1A1POLB | |
| SCHEMBL29424240 | 0.81 | MEN1 (0.85) | TDP1MAPTALDH1A1POLBKMT2A | |
| SCHEMBL5145183 | 0.80 | TDP1 (0.75) | TDP1KDM4EMAPTALDH1A1POLB | |
| SCHEMBL5145178 | 0.80 | TDP1 (0.75) | TDP1KDM4EMAPTALDH1A1POLB | |
| SCHEMBL21852274 | 0.77 | KDM4E (0.85) | TDP1KDM4EMAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718308-A4 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORP (CA) | 2007-07-18 | — | — | EP | disclosed |
| EP-1718308-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2006-11-08 | — | — | EP | disclosed |
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-12-22 | — | — | US | disclosed |
| WO-2005084141-A2 | NOVEL ABIETANE DITERPENOID COMPOUND, AND COMPOSITION COMPRISING EXTRACT OF TORREYA NUCIFERA, OR ABIETANE DITERPENOID COMPOUNDS OR TERPENOID COMPOUNDS ISOLATED FROM THEM FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005076695-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | TDP1 1996/4885KDM4E 4569/4885MAPT 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.